Organon & Co.
OGN
Rankning i aktier
#4348
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Aktiekurs
$13.76
Senast synkroniserad: 2026-10-20
Marknadsvärde
$3.61B
Förändring (1 dag)
0.07%
Förändring (1 år)
52.49%
Land
US
Handel Organon & Co. (OGN)
Kategori
Healthcare
Antal utestående aktier för Organon & Co. (OGN)
Antal utestående aktier per June 2026: 262.61M
Enligt de senaste finansiella rapporterna och aktiekursen för Organon & Co. är det aktuella antalet utestående aktier 262.61M. I slutet av December 2024 hade företaget 257.05M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Organon & Co. (OGN) från 2017 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 262.61M | 1.20% |
| 2025 | 259.50M | 0.95% |
| 2024 | 257.05M | 0.71% |
| 2023 | 255.24M | 0.46% |
| 2022 | 254.08M | 0.21% |
| 2021 | 253.55M | 0.01% |
| 2020 | 253.52M | 0.15% |
| 2019 | 253.13M | 0.00% |
| 2018 | 253.13M | 0.00% |
| 2017 | 253.13M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 892.40M | 239.82% |
US
|
|
| 2.45B | 832.01% |
US
|
|
| 1.77B | 574.38% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 203.11% |
CH
|
